P acemakers (PMs), automatic implantable cardioverterdefibrillators (AICDs), and cardiac resynchronization therapy systems (CRTs) are medical devices that regulate cardiac rate and rhythm and coordinate myocardial contraction. 1 Overall, these cardiac devices have been shown to improve symptoms, quality of life, and survival, 2,3 fueling increasing enthusiasm for their use. [4] [5] [6] [7] [8] The increased use, along with concerns about safety and effectiveness of the devices and the financial incentives associated with their use, has increased the need for data to track utilization and outcomes.
Multiple sources of data on cardiac devices exist. First, clinical trials are continually being conducted to study new indications and technologies. 3, [9] [10] [11] [12] [13] Second, reports of case series and retrospective reviews of medical records at local institutions offer lessons learned from practice about operative procedures and prevention of complications. [14] [15] [16] [17] [18] Third, device registries have been established to collect information on devices, operators, and implantation techniques, as well as on some aspects of outcomes. 19 For example, the Center for
Medicare & Medicaid Services (CMS) established an AICD registry in January 2005 and required hospitals to submit data on every implantation for Medicare payment. 20, 21 Fourth, the Food and Drug Administration (FDA), through MedSun and other reporting mechanisms, collects data from operators and manufacturers on device flaws, malfunctions, and adverse events, and issues advisories and recalls. [22] [23] [24] [25] [26] Fifth, surveys of operators and manufacturers have been conducted to monitor use in the Unites States 4, 5, 27 and worldwide. 28 Lastly, administrative data or hospital claims data have been used to track utilization in broad patient populations. 6, 7 Each of these data sources has advantages and weakness. Clinical trials provide robust data on efficacy, but are limited by their choice of patients and clinical settings. Case reports and retrospective reviews are rooted in real experience, but are limited in generalizability and by the size of observation sets. Registries usually have narrow focuses, such as on device flaws and malfunction. FDA voluntary reports are limited to what is voluntarily reported. Although lacking in clinical details and susceptible to coding errors, administrative data have several advantages over other data sources: primarily large size and nationwide coverage. 29 Administrative databased analysis is a convenient and efficient method when properly approached and can provide valuable information to supplement surveys, registries, case series, and clinical trials to study utilization, patient and hospital characteristics, patient outcomes, and associated factors.
This study explores the use of nationwide administrative data to assess the incidence of PM, AICD and CRT implantations, patient and hospital characteristics, selected perioperative outcomes, and relationships between them for the period 1997-2004. This study does not address clinical indications or the clinical benefits of the devices because of the nature of the data but rather focuses on nationwide utilization, characteristics and outcomes ascertainable from administrative data to provide a comprehensive scan of cardiac device utilization in the United States and pave the way for refined analyses that focus on specific clinical issues.
METHODS

Data and Variables
The primary source of data for this study was 
Identification of Patients with Cardiac Device Implantation
Cardiac device implantation was identified from ICD-9-CM procedure codes. Initial exploration showed that of 71,201 discharges with cardiac device procedure codes in the 2003 NIS, 37% had 1 code, 60% had 2, and 3% had 3 to 5 cardiac device procedure codes. The Appendix classifies these patients into 5 groups based on the code combination in each discharge record, and the footnote lists all specific procedure codes. If any uncertainty existed, a patient was placed into the "Other" group. The validity of these codes or this grouping has not been examined, but, given the clinical value of these procedures, it is unlikely that the procedure would not be coded in the discharge summary if it were performed, or, conversely, that the procedure would be coded if it were not performed. However, errors in choosing specific codes might occur, therefore some misclassification of patients was expected.
Patient Outcome Measures
Three groups of outcome measures were constructed. The first group included length of stay, hospital charges, and inhospital deaths, which were available from the source data. The second group was measures of complications or adverse events based on the AHRQ Patient Safety Indicators (PSIs). 35 The AHRQ PSIs include 20 indicators with reasonable validity, specificity, and potential for fostering quality improvement. Details on the development and validation of these indicators, the variables and ICD-9-CM codes used to define these PSIs, and the computer programs applying the PSIs to hospital discharge data were downloaded from the AHRQ website. 35 Our analysis included the following 6 PSIs of primary concern to patients who undergo cardiac device implantation: iatrogenic pneumothorax (PSI 6), postoperative hemorrhage or hematoma (PSI 9), postoperative pulmonary embolism or deep vein thrombosis (PSI 12), infection caused by medical care (PSI 7), postoperative sepsis (PSI 13), and accidental puncture/laceration (PSI 15). The third group of outcome measures was based on ICD-9-CM codes for mechanical complications caused by PM (99601) or by AICD (99604), recorded in the current hospitalization as a secondary diagnosis. Finally, a composite outcome measure was created to indicate whether a patient had any of the 7 types of complications identified through the PSIs and the ICD-9-CM codes for mechanical complications.
Statistical Method
National estimates on the numbers of cardiac device implantations by patient and hospital characteristics were estimated and tabulated. The diagnoses codes were examined and tabulated. Weighted estimates and standard errors were calculated for patient outcome measures. Student's t tests were used to determine statistically significant difference between 2 estimates when needed.
We conducted a series of multivariable regressions to explore the relationship between patient outcomes and patient and hospital characteristics such as patient comorbid conditions and hospital volume. General linear regressions were used to estimate the effects of patient and hospital characteristics on continuous outcomes variables (i.e., LOS and costs), and logistic regressions were used to estimate the effects of the characteristics on dichotomous outcomes variables (i.e., mortality and complication measures). P<0.05 and p<0.01 were considered statistically significant and highly significant, respectively. Table 1 Table 2 displays the associated patient and hospital characteristics for cardiac device implants performed in 2004. Patients aged 65 or over accounted for 70% of CRT patients, 60% of AICD patients, and over 85% of PM patients. Threequarters of CRT and AICD patients were male, whereas about half of the PM patients were male. Whites accounted for more than half of the patients. At least 75% of the patients had 1 or more chronic conditions. Approximately half of CRT implants were planned admissions, whereas most AICD and PM implants were during emergent admissions. Medicare was billed for three-quarters of all cardiac device implants. Most CRT and AICD implants were performed in large teaching hospitals and hospitals that implanted more than 300 primary PM, AICD, or CRT systems a year. PM implants were most often done in urban nonteaching hospitals, and equally distributed among low, medium, and high-volume hospitals.
More than 60% of patients with a new CRT had congestive heart failure as the principal diagnosis (table available upon request). The proportion of patients who had congestive heart failure as either the principal or a secondary diagnosis was 93%, 88%, 51%, 28%, and 41% in the 5 groups, respectively. Cardiac dysrhythmias were the most frequent primary diagnosis for new AICD and PM implants. Table 3 presents the national estimates for short-term patient outcomes for 2004. The length of stay was about 6 days for implanting primary PM, AICD, or CRT systems, but the charges and costs for CRT and AICD implantation were double that for PMs. In-hospital mortality risks were about 1% for Table 5 presents the effects of patient and hospital characteristics on in-hospital mortality for the 5 patient groups. Across the 5 patient groups, in-hospital mortality was higher among patients who were older, under Medicare coverage, with more comorbid diseases, or admitted through the emergency department. Smaller hospitals appeared to have lower in-hospital mortality rates, whereas urban teaching hospitals had higher in-hospital mortality rates. The data did not show a consistent volume-mortality relationship across the 5 patient groups. Table 6 presents the effects of patient and hospital characteristics on occurrence of complications. Again, patient frailty indicated by advanced age and comorbidity was significant. The relationships between other outcome measures and patient and hospital characteristics are not presented, but are available from the authors upon request. Overall, the estimates were similar to that for in-hospital mortality with some notable differences; for example, patients with more comorbid conditions were less likely to suffer from iatrogenic pneumothorax.
Short-term Patient Outcomes following Cardiac Device Implantations
Relationship between Patient Outcomes and Patient and Hospital Characteristics
DISCUSSION
This study showed steady increases in the number of AICDs and PMs implanted between 1997 and 2001. After the FDA approval of CRT in 2001, the growth in AICDs and PMs leveled off, and CRT implantations rapidly increased. In 2004, about 33,000 new CRT-D, 7,000 CRT-P, 67,000 new AICD, and 179,000 new PM systems were implanted the United States.
A survey of physicians and device companies estimated that 153,000 PMs and 29,000 AICDs were implanted in 1997. 5 Our administrative data-based estimates for the same year were 145,000 PMs and 27,000 AICDs, suggesting that administrative data are an alternative to assessment of cardiac device utilization in the United States.
Most patients who underwent cardiac device implantations were elderly whites with multiple chronic conditions. Most patients had principal diagnoses of congestive heart failure, cardiac dysrhythmia, or conduction disorder, and almost 100% of CRT-D patients had a primary or secondary diagnosis of congestive heart failure. These data suggest that administrative data could be used, to some extent, to assess whether cardiac devices are implanted in patients with proper indications. Further studies could be conducted in narrowly defined patient groups to examine patient indications.
Whereas most CRT and AICD implantations were done in large teaching hospitals that implanted 300 or more primary systems a year, PM implants were done more among nonteaching and low-volume hospitals. More research could be conducted to examine how patient characteristics and outcomes differ by hospital type, for example, whether patient outcomes are better in high-volume hospitals than in lowvolume hospitals.
Patients stayed in hospitals for about 5 days for AICD implantation in 2004, a substantial decrease from 9.19 days in 1997. In the meantime, the charges and costs increased steadily, from an average charge of $66,530 for an AICD in 1997 to $114,782 in 2004. CRT-D and AICD implantations were substantially more costly than CRT-P and PM. These cardiac device procedures had a substantially lower than average costto-charge ratio of 0.50, suggesting that patient admissions for cardiac device procedures might be more profitable than other hospital admissions. The rapid diffusion, especially the increase in CRT implantations, coupled with the profit potential, raises a question about the proper use of these devices.
Fewer than 2% of the patients died, and fewer than 4% of the patients had complications during hospitalization. As expected, iatrogenic pneumothorax was substantially more frequent in cardiac device implantations compared with that in surgical patients, which was reported at 0.09% in 2003, 36 whereas the rates of other complications in cardiac device patients were comparable to those in general surgical patients as documented by the 2006 National Healthcare Quality (6) 76 (4) 110 (5) 52 (1) 66 (2) Mean costs ($1000)
42 (1) 28 (1) 40 (1) 19 (1) 24 (1) In-hospital mortality (%) Report, where postoperative hemorrhage or hematoma, DVT/ PE, and accidental puncture were reported at 0.2%, 0.9%, and 0.4%, respectively. 36 Our analysis further showed that adverse outcomes were mostly associated with patient frailty indicated by advanced age, comorbidities, and emergency admission, and associated with the complexity of device implantations (i.e., AICDs and CRTs compared to pacemaker implantations). Given that the patients were mostly elderly with multiple 
